Trailing-twelve-month (TTM) revenue is $3.12 Billion with a year-over-year growth of +9.28%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $784,513,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $814,319,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $722,519,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $796,197,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $3,117,548,000 |
Current P/S: $6,539,898,880 market capitalization ÷ $3,117,548,000 TTM revenue = 2.10x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T13:45:12.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $796.20M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:45:31.215Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Amneal Specialty Pharma Segment | $356M | $378M | $374M | N/A | N/A | N/A |
| Av K A R E Segment | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Specialty Segment | $529M |
$3.12B
$3.12 Billion
+9.28%
vs. $2.85B a year ago (TTM)
+8.67%
5 Year compound annual growth rate
1 Year
+9.28%
3 Year
+10.48%
5 Year
+8.67%
10 Year
+13.29%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.02B | +$224.80M | +8.05% |
| 2024 | $2.79B | +$400.35M | +16.73% |
| 2023 | $2.39B | +$181.30M | +8.20% |
| 2022 | $2.21B | +$118.64M | +5.67% |
| 2021 | $2.09B | +$101.15M | +5.08% |
| 2020 |
TTM Growth
+9.28%
3-Year CAGR
+10.48%
5-Year CAGR
+8.67%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T13:45:31.215Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $406M |
| N/A |
| N/A |
| N/A |
| Av Kare | $294M | $349M | N/A | N/A | N/A | N/A |
|---|
| Generics Segment | $1.3B | $1.4B | $1.4B | $1.5B | N/A | N/A |
|---|
| Specialty Segment | N/A | N/A | N/A | $390M | $446M | $529M |
|---|
| $1.99B |
| +$366.15M |
| +22.51% |
| 2019 | $1.63B | ($36.62M) | (2.20%) |
| 2018 | $1.66B | +$629.34M | +60.88% |
| 2017 | $1.03B | +$15.43M | +1.52% |
| 2016 | $1.02B | +$151.94M | +17.54% |
